Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Dopaminergic receptors: structural features and functional implications].

A Nieoullon1, M Amalric

  • 1Laboratoire de Neurobiologie Cellulaire et Fonctionnelle du CNRS, 31, chemin Joseph-Aiguier, 13402 Marseille.

Revue Neurologique
|April 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Further contribution to the study of corticostriatal glutamatergic and nigrostriatal dopaminergic interactions within the striatal network: an in vivo voltammetric investigation.

Amino acids·2013
Same author

The nucleus accumbens 5-HTR₄-CART pathway ties anorexia to hyperactivity.

Translational psychiatry·2012
Same author

Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.

Neuropharmacology·2012
Same author

Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity.

Neurobiology of disease·2012
Same author

Comparative analysis of the effects of in vivo electrical stimulation of the frontal cortex and gamma-butyrolactone administration on dopamine and dihydroxyphenyl acetic acid (DOPAC) striatal contents in the rat.

Neurochemistry international·2010
Same author

Brain glutamate uptake: Regional distribution study from sensorimotor areas in the cat.

Neurochemistry international·2010
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
See all related articles

Dopamine receptors (D1-like and D2-like) have diverse functions in the brain. Selective agonists offer potential for treating Parkinson's disease symptoms, including motor and cognitive deficits.

Area of Science:

  • Neuropharmacology
  • Molecular Biology
  • Neuroscience

Context:

  • Dopamine receptors are classified into D1-like (D1, D5) and D2-like (D2, D3, D4) subclasses.
  • Diverse transduction mechanisms explain dopamine's varied cellular actions in the brain.
  • Receptor distribution links dopamine to motor, limbic, and cognitive behaviors.

Purpose:

  • To explore the role of dopaminergic receptor subtypes in Parkinson's disease.
  • To discuss adaptive cellular responses to dopamine depletion in Parkinson's disease.
  • To evaluate the therapeutic potential of dopamine receptor agonists.

Summary:

  • Molecular and biochemical methods have elucidated dopamine receptor subtypes and their signaling pathways.
  • Parkinson's disease involves dopamine depletion, leading to adaptive cellular responses.

Related Experiment Videos

  • Selective dopamine receptor agonists are crucial for managing Parkinson's motor symptoms and L-DOPA side effects.

    • Impact:

    • Development of selective agonists is key to addressing Parkinson's motor and cognitive deficits.
    • Understanding dopamine receptor subtypes enhances therapeutic strategies for neurological disorders.
    • Targeting dopamine pathways offers a promising avenue for neurodegenerative disease treatment.